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Are HUS and TTP genetically determined?
Hemolytic uremic syndrome (HUS), and the related condition
thrombotic thrombocytopenic purpura (TTP), are diseases of
non-immune hemolytic anemia, thrombocytopenia and renal fail-
ure with platelet thrombi in the microcirculation of various organs
[1].
The characteristic lesion, thrombotic microangiopathy (TMA),
is unique to these syndromes and consists of vessel wall thicken-
ing, with swelling and detachment of endothelial cells from the
basement membrane and with accumulation of fluffy material in
the subendothelium [1]. The typical form of HUS of children
manifests with bloody diarrhea mostly associated to Escherichia
coli infection and lesions are related to a toxin, Shiga-like toxin or
verocytotoxin, unique of certain strain of E. coli. There are
hereditary forms of HUS mostly with a recessive trait, with
dominant inheritance occasionally reported [2]. In affected fam-
ilies members may have HUS as the sole manifestation of the
disease, in other instances clinical manifestation may rather be
reminiscent of TTP. Occasionally clinical manifestation of both
HUS and TTP can co-exist in the same patient [2].
A recent report [3] of increased incidence of HLA B40 group
antigens in children with HUS was taken to suggest that HLA B40
is linked to susceptibility genes, as to cause disease manifestation
upon concomitant exposure to triggering factors. HUS recurrence
in renal allografts as well as improvement following plasma
exchange, at least in some patients with familial HUS, would
suggest a genetic abnormality in plasma proteins, that, together
with findings of reduced levels of C3 consistently reported since
1974 in sporadic and familial variants of the disease, have
suggested an inherited defect of C3 synthesis. A major step
forward in defining and understanding underlying genetic defect
of familial HUS was made by three distinct reports published from
1981 to 1994 [4–6], showing a genetic deficiency of factor H—a
regulatory protein of the alternative complement pathway—in
HUS, leading to low levels of complement protein C3. In the more
recent of the above studies [6] HUS was reported in two siblings:
one died at an early age from diarrhea-associated HUS, while the
other had three episodes of HUS since the age of 19 years. This
latter patient and her sister, who was asymptomatic at that time,
were both found to have very low factor H (5% of normal).
Several members of the family had 50% levels, suggesting an
autosomal recessive defect. In this issue of Kidney International,
Warwicker et al [7] demonstrated in three large families with
HUS, that an area on chromosome 1q, that contains the gene for
factor H, segregates with the disease, which further supports that
low C3 in the setting of familial HUS depends on an inherited
factor H deficiency. At variance with the family described earlier
by Pichette and coworkers [6], factor H levels were not reduced in
any members of the three families. The authors state that normal
levels of factor H do not exclude an underlying functional
abnormality. Actually, in affected members and obligate carriers
within one family they found a point mutation in short consensus
repeat (SCR) 20—factor H protein is composed of 20 homolo-
gous SCR domains—causing an arginine to glycine change.
Factor H molecule, in addition to the two C3b binding sites
originally described which are located on 1–4 and 6–10 domains,
has been recently found to have a third C3b binding site that
resides in the 16–20 region. It is therefore theoretically possible
that the point mutation described by Warwicker et al [7] in exon
20 might alter the structure and hence the function of factor H;
however, functional and mutagenesis studies are mandatory to
clarify its real significance in the context of disease pathophysiol-
ogy. In the other two families, no mutations were detected in the
coding region of factor H gene, although mutations in the
promoter or within introns cannot be excluded. Given the fact that
linkage analysis has been performed on a huge candidate region,
which includes other genes encoding for complement regulatory
proteins (DAF, CR1 and factor H-related proteins) [8], it is more
plausible that other genes, possibly including some of the above,
are actually involved in causing hereditary HUS. Warwicker et al
[7] also described a mutation of factor H gene in an individual
with relapsing HUS but with no familial history of HUS. The
mutation comprises a deletion causing a premature termination
codon that results in 50% reduced levels of factor H. These data
raise the intriguing possibility of negative family history being still
compatible with a genetically determined HUS, and even that de
novo mutations in factor H and other related genes might
predispose to the disease. In their paper the authors refer to
unpublished results from their laboratory describing a polymor-
phism in an NF-kB responsive element in the promoter region of
factor H and speculate that polymorphic variants might confer a
genetic predisposition to post-infectious HUS. The speculation is
based on the fact that in the siblings who suffered HUS already
reported by Pichette, one had recurrent HUS and factor H
deficiency and the other presented with typical diarrhea-associ-
ated HUS (factor H was not measured in the latter, however).
While the possibility that polymorphisms in the promoter and in
the coding region of factor H might have a role in familial and
recurrent HUS appears very fascinating, one may also ask the
question of whether congenital defects of the complement system
may have a role in driving predisposition to HUS following E. coli
infections.
Can factor H be regarded now as the candidate gene involved
in familiar predisposition to HUS? It is possible. Certainly
investigating C3 and factor H levels in individuals with familial
and recurrent history of HUS is something that needs to be done
in the future. The heterogeneity of the manifestations of HUS
(typical, recurrent, familial with autosomal dominant inheritance,
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and familial with autosomal recessive inheritance), clearly indi-
cates that much work is yet to be done and it is likely that more
than one gene is involved.
We recently looked for possible complement alterations in
patients with familial forms of TTP, and found a high incidence of
low C3 levels exactly as observed with HUS [9]. Of interest, in two
families who had one member affected with HUS and one with
TTP, low C3 levels were found both in patients and in some of
their relatives. Altogether these preliminary results support the
concept that HUS and TTP are different manifestations of the
same inherited defect. Perhaps genetics will contribute to resolve
the old issue of whether HUS and TTP are the same or different
diseases [10].
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